دورية أكاديمية
Treatment with Rasburicase in Hospitalized Patients with Cardiorenal Syndrome: Old Treatment, New Scenario
العنوان: | Treatment with Rasburicase in Hospitalized Patients with Cardiorenal Syndrome: Old Treatment, New Scenario |
---|---|
المؤلفون: | Rosa Melero, Beatriz Torroba-Sanz, Marian Goicoechea, Iago Sousa-Casasnovas, Jose María Barrio, Ana María García-Prieto, Patrocinio Rodriguez-Benitez, Xandra García-González, María Sanjurjo-Sáez |
المصدر: | International Journal of Molecular Sciences, Vol 25, Iss 6, p 3329 (2024) |
بيانات النشر: | MDPI AG, 2024. |
سنة النشر: | 2024 |
المجموعة: | LCC:Biology (General) LCC:Chemistry |
مصطلحات موضوعية: | cardiorenal syndrome, hyperuricaemia, rasburicase, uricase, diuretic resistance, continuous renal replacement therapy, Biology (General), QH301-705.5, Chemistry, QD1-999 |
الوصف: | Cardiorenal syndrome (CRS) involves joint dysfunction of the heart and kidney. Acute forms share biochemical alterations like hyperuricaemia (HU) with tumour lysis syndrome (TLS). The mainstay treatment of acute CRS with systemic overload is diuretics, but rasburicase is used in TLS to prevent and treat hyperuricaemia. An observational, retrospective study was performed to assess the effectiveness and safety of a single dose of rasburicase in hospitalized patients with cardiorenal syndrome, worsening renal function and uric acid levels above 9 mg/dL. Rasburicase improved diuresis and systemic congestion in the 35 patients included. A total of 86% of patients did not need to undergo RRT, and early withdrawal was possible in the remaining five. Creatinine (Cr) decreased after treatment with rasburicase from a peak of 3.6 ± 1.27 to 1.79 ± 0.83 mg/dL, and the estimated glomerular filtration rate (eGFR) improved from 17 ± 8 to 41 ± 20 mL/min/1.73 m2 (p = 0.0001). The levels of N-terminal type B Brain Natriuretic Peptide (Nt-ProBNP) and C-reactive protein (CRP) were also significantly reduced. No relevant adverse events were detected. Our results show that early treatment with a dose of rasburicase in patients with CRS and severe HU is effective to improve renal function and systemic congestion, avoiding the need for sustained extrarenal clearance, regardless of comorbidities and ventricular function. |
نوع الوثيقة: | article |
وصف الملف: | electronic resource |
اللغة: | English |
تدمد: | 1422-0067 1661-6596 |
العلاقة: | https://www.mdpi.com/1422-0067/25/6/3329Test; https://doaj.org/toc/1661-6596Test; https://doaj.org/toc/1422-0067Test |
DOI: | 10.3390/ijms25063329 |
الوصول الحر: | https://doaj.org/article/99d40465ca144cf58fc7df35cf18a704Test |
رقم الانضمام: | edsdoj.99d40465ca144cf58fc7df35cf18a704 |
قاعدة البيانات: | Directory of Open Access Journals |
تدمد: | 14220067 16616596 |
---|---|
DOI: | 10.3390/ijms25063329 |